INOVIO Pharmaceuticals
NEWS ALERT

FDA Accepts for Review INOVIO’s BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)

Press Releases

INOVIO to Participate in Upcoming Scientific and Investor Conferences

Posted on February 12, 2026

INOVIO to Participate in Upcoming Scientific and Investor Conferences

Posted on February 12, 2026

FDA Accepts for Review INOVIO’s BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)

Posted on December 29, 2025

FDA Accepts for Review INOVIO’s BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)

Posted on December 29, 2025

INOVIO Reports Inducement Grant Under Inducement Plan

Posted on December 19, 2025

INOVIO Reports Inducement Grant Under Inducement Plan

Posted on December 19, 2025

INOVIO to Participate in December Investor Conferences

Posted on November 18, 2025

INOVIO to Participate in December Investor Conferences

Posted on November 18, 2025

INOVIO Announces Pricing of $25 Million Public Offering

Posted on November 11, 2025

INOVIO Announces Pricing of $25 Million Public Offering

Posted on November 11, 2025

SUBSCRIBE FOR UPDATES FROM INOVIO
Register to receive email alerts for INOVIO press releases

© Copyright 2026 INOVIO Pharmaceuticals. All rights reserved.